public/data/source_tsvs/CancerCommons_INTERACTIONS.tsv
primary_gene_name entrez_gene_id reported_gene_name pubchem_drug_id pubchem_drug_name source_reported_drug_name drug_trade_name drug_development_name primary_drug_name drug_class interaction_type pharmaceutical_developer data_source cancer_type
BRAF 673 BRAF (V660) E/K 42611257 PLX4032 Vemurafenib/Zelboraf/PLX4032 RO 5185426 Vemurafenib Zelboraf Zelboraf RAF Inhibitor Inhibition Genentech CancerCommons Melanoma
BRAF 673 BRAF 44462760 GSK 2118436 Dabrafenib/GSK2118436 Dabrafenib Dabrafenib Dabrafenib RAF Inhibitor Inhibition GlaxoSmithKline CancerCommons Melanoma
BRAF 673 BRAF na na LGX818 LGX818 LGX818 LGX818 RAF Inhibitor Inhibition Novartis CancerCommons Melanoma
BRAF 673 Pan-RAF 11656518 RAF265 RAF265/CHIR-265 pan-RAF RAF265 CHIR-265 CHIR-265 RAF Inhibitor Inhibition Novartis CancerCommons Melanoma
BRAF 673 BRAF V600E na na RO5212054 /PLX3603/ RO5212054 PLX3603 PLX3603 RAF Inhibitor Inhibition Hoffmann-La Roche CancerCommons Melanoma
MAP2K1 5604 MEK na na RO4987655 RO4987655 RO4987655 RO4987655 MEK Inhibitor Inhibition Hoffmann-La Roche CancerCommons Melanoma
MAP2K1 5604 MEK 11707110 GSK 1120212 MEK162 trametinib/ GSK1120212 Trametinib GSK1120212 Mekinist MEK Inhibitor Inhibition GlaxoSmithKline CancerCommons Melanoma
MAP2K1 5604 MEK 16222096 GDC-0973 GDC-0973/XL518 XL518 GDC-0973 GDC-0973 MEK Inhibitor Inhibition Exelixis CancerCommons Melanoma
MAP2K1 5604 MEK 24963252 TAK-733 TAK-733 TAK-733 TAK-733 TAK-733 MEK Inhibitor Inhibition Millennium Pharmaceuticals CancerCommons Melanoma
MAP2K1 5604 MEK 10127622 AZD6244 AZD6244/selumetinib Selumetinib AZD6244 AZD6244 MEK Inhibitor Inhibition AstraZenica CancerCommons Melanoma
MAP2K1 5604 MEK 44187362 N-(2,3-dihydroxypropyl)-1-((2-fluoro-4-iodophenyl)amino)isonicotinamide MSC1936369B/pimasertib Pimasertib MSC1936369B MSC1936369B MEK Inhibitor Inhibition Merck CancerCommons Melanoma
MAP2K1 5604 MEK 44182295 BAY86-9766 BAY86-9766/refametinib Refametinib BAY86-9766 BAY86-9766 MEK Inhibitor Inhibition Ardea Biosciences CancerCommons Melanoma
PIK3CA 5290 PI3K 9849735 PX-866 PX-866 PX-866 PX-866 PX-866 PI3K Inhibitor Inhibition Oncothyreon CancerCommons Melanoma
PIK3CA 5290 PI3K 16654980 BKM120 BKM120 BKM120 BKM120 BKM120 PI3K Inhibitor Inhibition Novartis CancerCommons Melanoma
PIK3CA 5290 PI3K na na SAR260301 SAR260301 SAR260301 SAR260301 PI3K Inhibitor Inhibition Sanofi-Aventis CancerCommons Melanoma
PIK3CA 5290 PI3K 11977753 Dactolisib BEZ235 BEZ235 BEZ235 BEZ235 PI3K/mTOR dual Inhibitor Inhibition Novartis CancerCommons Melanoma
mTOR 2475 PI3K/mTOR 11977753 Dactolisib BEZ235 BEZ235 BEZ235 BEZ235 PI3K/mTOR dual Inhibitor Inhibition Novartis CancerCommons Melanoma
PIK3CA 5290 PI3K 49867926 XL765 SAR245409 SAR245409 XL765 XL765 PI3K/mTOR dual Inhibitor Inhibition Sanofi CancerCommons Melanoma
mTOR 2475 PI3K/mTOR 49867926 XL765 SAR245409 SAR245409 XL765 XL765 PI3K/mTOR dual Inhibitor Inhibition Sanofi CancerCommons Melanoma
PIK3CA 5290 PI3K 66563707 BAY80-6946 BAY80-6946 BAY80-6946 BAY80-6946 BAY80-6946 PI3K Inhibitor Inhibition Bayer CancerCommons Melanoma
AKT1 207 AKT 46930998 MK2206 MK2206 MK2206 MK2206 MK2206 AKT Allosteric Inhibitor Allosteric Inhibitor Merck CancerCommons Melanoma
CDK4 1019 CDK4/6 11431660 PD 0332991 PD0332991 Palbociclib PD0332991 Palbociclib CDK/Rb Inhibitor Inhibition Pfizer CancerCommons Melanoma
CDK6 1021 CDK4/6 11431660 PD 0332991 PD0332991 Palbociclib PD0332991 Palbociclib CDK/Rb Inhibitor Inhibition Pfizer CancerCommons Melanoma
CDK1 983 CDK1,2,5,9 46926350 Dinaciclib Dinaciclib (SCH727965) Dinaciclib SCH727965 SCH727965 Pan-CDK Inhibitor Inhibition Merck CancerCommons Melanoma
CDK2 1017 CDK1,2,5,9 46926350 Dinaciclib Dinaciclib (SCH727965) Dinaciclib SCH727965 SCH727965 Pan-CDK Inhibitor Inhibition Merck CancerCommons Melanoma
CDK5 1020 CDK1,2,5,9 46926350 Dinaciclib Dinaciclib (SCH727965) Dinaciclib SCH727965 SCH727965 Pan-CDK Inhibitor Inhibition Merck CancerCommons Melanoma
CDK9 1025 CDK1,2,5,9 46926350 Dinaciclib Dinaciclib (SCH727965) Dinaciclib SCH727965 SCH727965 Pan-CDK Inhibitor Inhibition Merck CancerCommons Melanoma
CDK2 1017 CDK2,7,9 3025986 N-(5-(((5-(1,1-dimethylethyl)-2-oxazolyl)methyl)thio)-2-thiazolyl)-4-piperidinecarboxamide SNS-032 SNS-032 SNS-032 SNS-032 Pan-CDK Inhibitor Inhibition Sunesis CancerCommons Melanoma
CDK7 1022 CDK2,7,9 3025986 N-(5-(((5-(1,1-dimethylethyl)-2-oxazolyl)methyl)thio)-2-thiazolyl)-4-piperidinecarboxamide SNS-032 SNS-032 SNS-032 SNS-032 Pan-CDK Inhibitor Inhibition Sunesis CancerCommons Melanoma
CDK9 1025 CDK2,7,9 3025986 N-(5-(((5-(1,1-dimethylethyl)-2-oxazolyl)methyl)thio)-2-thiazolyl)-4-piperidinecarboxamide SNS-032 SNS-032 SNS-032 SNS-032 Pan-CDK Inhibitor Inhibition Sunesis CancerCommons Melanoma
CDK4 1019 CDK4/6 na na LY2835219 LY2835219 LY2835219 LY2835219 CDK/Rb Inhibitor Inhibition Eli Lilly CancerCommons Melanoma
CDK6 1021 CDK4/6 na na LY2835219 LY2835219 LY2835219 LY2835219 CDK/Rb Inhibitor Inhibition Eli Lilly CancerCommons Melanoma
CDK1 983 Pan CDK na na BAY1000394 BAY1000394 BAY1000394 BAY1000394 Pan-CDK Inhibitor Inhibition Bayer CancerCommons Melanoma
CDK2 1017 Pan CDK na na BAY1000394 BAY1000394 BAY1000394 BAY1000394 Pan-CDK Inhibitor Inhibition Bayer CancerCommons Melanoma
CDK4 1019 Pan CDK na na BAY1000394 BAY1000394 BAY1000394 BAY1000394 Pan-CDK Inhibitor Inhibition Bayer CancerCommons Melanoma
CDK9 1025 Pan CDK na na BAY1000394 BAY1000394 BAY1000394 BAY1000394 Pan-CDK Inhibitor Inhibition Bayer CancerCommons Melanoma
HSP90AA1 3320 HSP90 23624255 STA-9090 STA-9090(Ganetespib) Ganetespib STA-9090 STA-9090 Chaperone Inhibitor Inhibition Synta Pharmaceuticals CancerCommons Melanoma
HSP90AA1 3320 HSP90 71301280 XL888 XL888 XL888 XL888 XL888 Chaperone Inhibitor Inhibition Exelixis CancerCommons Melanoma
NOTCH1 4851 Gamma-Secretase 49867930 RO4929097 RO4929097 RO4929097 RO4929097 RO4929097 Notch Inhibitor Inhibition Roche CancerCommons Melanoma
MET 4233 MET 25102847 Cabozantinib Cabozantinib (XL184) Cabozantinib XL184 Cometriq MET Inhibitor Inhibition Exelixis CancerCommons Melanoma
MET 4233 MET na na INC280 INC280 INC280 INC280 MET Inhibitor Inhibition Novartis CancerCommons Melanoma
FGFR1 2260 FGFRs 53235510 BGJ398 BGJ398 BGJ398 BGJ398 BGJ398 Pan-FGFR Inhibitor Inhibition Novartis CancerCommons Melanoma
FGFR2 2263 FGFRs 53235510 BGJ398 BGJ398 BGJ398 BGJ398 BGJ398 Pan-FGFR Inhibitor Inhibition Novartis CancerCommons Melanoma
FGFR3 2261 FGFRs 53235510 BGJ398 BGJ398 BGJ398 BGJ398 BGJ398 Pan-FGFR Inhibitor Inhibition Novartis CancerCommons Melanoma
FGFR4 2264 FGFRs 53235510 BGJ398 BGJ398 BGJ398 BGJ398 BGJ398 Pan-FGFR Inhibitor Inhibition Novartis CancerCommons Melanoma
IGF1R 3480 IGF1 Receptor na na AMG 479 (human antibody) AMG 479 AMG 479 AMG 479 Monoclonal Antibody Antibody Amgen CancerCommons Melanoma
KIT 3815 KIT 644241 Nilotinib Nilotinib/AMNN107 (approved for CML+) Tasigna AMNN107 Nilotinib Kit Inhibitor Inhibition Novartis CancerCommons Melanoma
KIT 3815 KIT 10074640 Masitinib Masitinib Masitinib Masitinib Masitinib Kit Inhibitor Inhibition AB Science CancerCommons Melanoma
KIT 3815 KIT 3062316 Dasatinib Dasatinib Sprycel Dasatinib Dasatinib Kit Inhibitor Inhibition Bristol-Myers Squibb CancerCommons Melanoma
KIT 3815 KIT na na PLX108-01 PLX108-01 PLX108-01 PLX108-01 Kit Inhibitor Inhibition Plexxicon CancerCommons Melanoma
FLT3 2322 KIT na na Immunotherapies in testing with BRAFi or KITi: PLX108-01 PLX108-01 PLX108-01 Kit Inhibitor Inhibition Plexxicon CancerCommons Melanoma
CD274 29126 Anti-PD-L1 na na MPDL3280A/ RG7446 (human antibody) MPDL3280A RG7446 RG7446 Monoclonal Antibody Antibody Genentech CancerCommons Melanoma
PDCD1 5133 Anti-PD-1 na na CT-011 CT-011 CT-011 CT-011 Monoclonal Antibody Antibody Teva and CureTech CancerCommons Melanoma
CTLA4 1493 Anti-CTLA4 na na Yervoy/ipilimumab Yervoy Ipilimumab Ipilimumab Monoclonal Antibody Antibody Bristol-Myers Squibb CancerCommons Melanoma
EGFR 1956 EGFR 176870 Erlotinib Erlotinib Tarceva Erlotinib Erlotinib EGFR Inhibitor Inhibition Roche CancerCommons Lung
EGFR 1956 EGFR 11511120 PF 00299804 PF-00299804/Dacomitinib Dacomitinib PF-00299804 PF-00299804 EGFR Inhibitor Inhibition Pfizer CancerCommons Lung
EGFR 1956 EGFR 56842117 IFL Protocol Cetuximab Erbitux Cetuximab Cetuximab Monoclonal Antibody Antibody Bristol-Myers Squibb CancerCommons Lung
EGFR 1956 EGFR 123631 Gelfitinib Gelfitinib/Iressa Iressa Gelfitinib Gelfitinib EGFR Inhibitor Inhibition AstraZeneca CancerCommons Lung
EGFR 1956 EGFR 10184653 BIBW 2992 Afatinib Afatinib BIBW2992 BIBW2992 EGFR Inhibitor Inhibition Boehringer Ingelheim CancerCommons Lung, Prostate
ALK 238 ALK, ROS 25134326 ASP3026 ASP3026 ASP3026 ASP3026 ASP3026 ALK Inhibitor Inhibition Astellas Pharma CancerCommons Lung
ALK 238 ALK, ROS 11626560 Crizotinib Crizotinib/Xalkori/PF-02341066 Xalkori PF-02341066 Crizotinib ALK Inhibitor Inhibition Pfizer CancerCommons Lung
ROS1 6098 ALK, ROS 25134326 ASP3026 ASP3026 ASP3026 ASP3026 ASP3026 ALK Inhibitor Inhibition Astellas Pharma CancerCommons Lung
ROS1 6098 ALK, ROS 11626560 Crizotinib Crizotinib/Xalkori/PF-02341066 Xalkori PF-02341066 Crizotinib ALK Inhibitor Inhibition Pfizer CancerCommons Lung
ALK 238 ALK na na X-396 X-396 X-396 X-396 ALK Inhibitor Inhibition Xcovery CancerCommons Lung
ALK 238 ALK na na LDK378 LDK378 LDK378 LDK378 ALK Inhibitor Inhibition Novartis CancerCommons Lung
MET 4233 MET 42642645 GSK1363089 GSK1363089 Foretinib GSK1363089 GSK1363089 MET/VEGFR Inhibitor Inhibition GlaxoSmithKline CancerCommons Lung
MET 4233 MET na na Onartuzumab Onartuzumab Onartuzumab Onartuzumab MET Inhibitor Inhibition Genentech CancerCommons Lung, Prostate
MET 4233 MET 11494412 ARQ 197 ARQ 197/Tivantinib Tivantinib ARQ 197 ARQ 197 MET Inhibitor Inhibition ArQule and Daiichi Sankyo CancerCommons Lung, Prostate
MET 4233 MET, VEGFRs, Axl, Tie2, Ron 24901704 MGCD265 MGCD265 MGCD265 MGCD265 MGCD265 MET Inhibitor Inhibition MethylGene CancerCommons Lung
HGF 3082 HGF (MET Ligand) na na AMG 102/Rilotumumab Rilotumumab AMG 102 AMG 102 Monoclonal Antibody Inhibition Amgen CancerCommons Lung
IGF1R 3480 IGF1R 11640390 3-(8-amino-1-(2-phenylquinolin-7-yl)imidazo(1,5-a)pyrazin-3-yl)-1-methylcyclobutanol OSI-906 OSI-906 OSI-906 Linsitinib IGF1R Inhibitor Inhibition OSI Pharmaceuticals CancerCommons Lung
FLT1 2321 VEGFR 9911830 Tivozanib Tivozanib Tivozanib AV951 AV951 VEGFR Inhibitor Inhibition Aveo Oncology CancerCommons Lung
FLT1 2321 VEGFR 11226834 Cediranib maleate Cediranib maleate/ AZD2171/Recentin Cediranib AZD2171 Recentin VEGFR Inhibitor Inhibition AstraZeneca CancerCommons Lung
PIK3CA 5289 PI3K/mTOR 56649450 BYL719 BYL719 BYL719 BYL719 BYL719 PI3K/mTOR dual Inhibitor Inhibition Novartis CancerCommons Lung
mTOR 2475 PI3K/mTOR 56649450 BYL719 BYL719 BYL719 BYL719 BYL719 PI3K/mTOR dual Inhibitor Inhibition Novartis CancerCommons Lung
mTOR 2475 mTOR na na DS-3078a DS-3078a DS-3078a DS-3078a mTOR Inhibitor Inhibition Daiichi Sankyo CancerCommons Lung
KRAS 3485 KRAS-RAS na na Reolysin Reolysin Reolysin Reolysin Ras Inhibitor Inhibition Oncolytics Biotech CancerCommons Lung
mTOR 2475 TORC na na CC-223 CC-223 CC-223 CC-223 mTOR Inhibitor Inhibition Celgene CancerCommons Lung
mTOR 2475 mTOR 6918289 Temsirolimus Temsirolimus Torisel Temsirolimus Temsirolimus mTOR Inhibitor Inhibition Wyeth Pharmaceuticals CancerCommons Lung
AURKA 6790 Aurora Kinase 24771867 MLN 8237 MLN8237 Alisertib MLN8237 MLN8237 AurK Inhibitor Inhibition Millenium CancerCommons Lung
HSP90AA1 3320 HSP90 11955716 AT13387 AT13387 AT13387 AT13387 AT13387 HSP90 Inhibitor Inhibition Astex Pharmaceuticals CancerCommons Lung
HSP90AA1 3320 HSP90 10096043 AUY922 AUY922 AUY922 AUY922 AUY922 HSP90 Inhibitor Inhibition Novartis CancerCommons Lung
CYP17A1 1586 CYP17 57336518 17-(3-pyridyl)-5,16-androstadien-3beta-acetate Zytiga/abiraterone acetate (FDA-approved) Zytiga abiraterone acetate Abiraterone Acetate Cytochrome Inhibitor Inhibition Janssen Biotech CancerCommons Prostate
AR 367 Androgen receptor 15951529 MDV 3100 Xtandi/MDV3100/enzalutamide (FDA-approved) Xtandi MDV 3100 Enzalutamide Androgen Inhibitor Inhibition Astellas Pharma CancerCommons Prostate
CYP17A1 1586 CYP17 9883029 Orteronel Orteronel/TAK700 Orteronel TAK700 Orteronel Cytochrome Inhibitor Inhibition Millennium Pharmaceuticals CancerCommons Prostate
AR 367 Androgen receptor na na ODM-201 ODM-201 ODM-201 ODM-201 Androgen Inhibitor Inhibition Orion Pharmaceuticals CancerCommons Prostate
FOLH1 2346 PSMA na na BIND-014/PSMA-targeted docetaxel nanoparticle Docetaxel Docetaxel Docetaxel Folate Inhibitor Inhibition BIND Biosciences CancerCommons Prostate
FGFR3 2261 FGFR3 and others (VEGFR) 9886808 4-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one Dovitinib/TKI258 Dovitinib TK1258 Dovitinib FGFR Inhibitor Inhibition Novartis CancerCommons Prostate
FLT1 2321 FGFR3 and others (VEGFR) 9886808 4-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one Dovitinib/TKI258 Dovitinib TK1258 Dovitinib FGFR Inhibitor Inhibition Novartis CancerCommons Prostate
FLT1 2321 VEGF, PDGF 6450551 Axitinib Axitinib/AG013736/Inlyta Inlyta AG013736 Axitinib Kinase Inhibitor Inhibition Novartis CancerCommons Prostate
FLT4 2324 VEGF, PDGF 6450551 Axitinib Axitinib/AG013736/Inlyta Inlyta AG013736 Axitinib Kinase Inhibitor Inhibition Novartis CancerCommons Prostate
KDR 3791 VEGF, PDGF 6450551 Axitinib Axitinib/AG013736/Inlyta Inlyta AG013736 Axitinib Kinase Inhibitor Inhibition Novartis CancerCommons Prostate
PDGFB 5155 VEGF, PDGF 6450551 Axitinib Axitinib/AG013736/Inlyta Inlyta AG013736 Axitinib Kinase Inhibitor Inhibition Novartis CancerCommons Prostate
KIT 3815 VEGF, PDGF 6450551 Axitinib Axitinib/AG013736/Inlyta Inlyta AG013736 Axitinib Kinase Inhibitor Inhibition Pfizer CancerCommons Prostate
IGF1R 3480 IGF1-R na na Cixutumumab/IMC-A12 Cixutumumab IMC-A12 Cixutumumab Monoclonal Antibody Antibody ImClone Systems CancerCommons Prostate
EGFR 1956 EGFR 208908 Lapatinib Lapatinib Lapatinib Lapatinib Lapatinib EGFR inhibitor Inhibition GlaxoSmithKline CancerCommons Prostate
KIT 3815 Receptor tyrosine kinases KIT, CSF1R, and FLT3 na na PLX3397 PLX3397 PLX3397 PLX3397 Kinase Inhibitor Inhibition Plexxicon CancerCommons Prostate
CSF1R 1436 Receptor tyrosine kinases KIT, CSF1R, and FLT3 na na PLX3397 PLX3397 PLX3397 PLX3397 Kinase Inhibitor Inhibition Plexxicon CancerCommons Prostate
FLT3 2322 Receptor tyrosine kinases KIT, CSF1R, and FLT3 na na PLX3397 PLX3397 PLX3397 PLX3397 Kinase Inhibitor Inhibition Plexxicon CancerCommons Prostate
PTK2 5747 FAK, PYK2 11713159 PF00562271 PF00562271 PF00562271 PF00562271 PF00562271 FAK Inhibitor Inhibition Merck CancerCommons Prostate
PTK2B 2185 FAK, PYK2 11713159 PF00562271 PF00562271 PF00562271 PF00562271 PF00562271 FAK Inhibitor Inhibition Merck CancerCommons Prostate
SRC 6714 SRC 3062316 Dasatinib Dasatinib/Sprycel/ BMS-354825 Dasatinib Sprycel Dasatinib Kit Inhibitor Inhibition Bristol-Myers Squibb CancerCommons Prostate
EIF4E 1977 EIF4E na na ISIS-EIF4ERx ISIS-EIF4ERx ISIS-EIF4ERx ISIS-EIF4ERx eIF Inhibitor Inhibition Isis Pharmaceuticals CancerCommons Prostate
CLU 1191 Clusterin 70689314 CHEMBL2103801 OGX-011/custirsen Custirsen OGX-011 OGX-011 CLU Inhibitor Inhibition OncoGenex CancerCommons Prostate
HSPB1 3315 HSP27 na na OGX-427 OGX-427 OGX-427 OGX-427 HSP27 Inhibitor Inhibition OncoGenex CancerCommons Prostate
PARP1 142 PARP 11960529 2-((R)-2-methylpyrrolidin-2-yl)-1H-benzimidazole-4-carboxamide Veliparib/ABT-888 Veliparib ABT-888 ABT-888 PARP Inhibitor Inhibition Active Biochem CancerCommons Prostate
PARP2 10038 PARP 11960529 2-((R)-2-methylpyrrolidin-2-yl)-1H-benzimidazole-4-carboxamide Veliparib/ABT-888 Veliparib ABT-888 ABT-888 PARP Inhibitor Inhibition Active Biochem CancerCommons Prostate
HDAC1 3065 HDAC 49855250 SB939 Pracinostat SB939 Pracinostat SB939 SB939 HDAC Inhibitor Inhibition MEI Pharma CancerCommons Prostate
HDAC1 3065 HDAC 6918837 Panobinostat Panobinostat Panobinostat Panobinostat Panobinostat HDAC Inhibitor Inhibition Novartis CancerCommons Prostate